Compare Neurocrine Biosciences Inc (NBIX) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Public Storage — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Public Storage trades at $285.55 (market cap $52.69B). The key difference: Public Storage is far larger — about 3.6× Neurocrine Biosciences Inc's market cap, and Public Storage pays a 4.26% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Public Storage for 130 Days on average.
| NBIX | PSA | |
|---|---|---|
Market Cap | $14.60B | $52.69B |
Volume | 1,075,694 | 975,662 |
Sector | Health | Real Estate |
52-Week High | $185.50 | $330.47 |
52-Week Low | $123.10 | $258.44 |
Typical Hold Time | 23 Days | 130 Days |
Enterprise Value | $14.61B | $66.96B |
Dividend Yield | — | 4.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Public Storage (PSA) trades at $285.52, down 0.12% on the day, with a bearish technical signal. The stock shows strong profitability with a 41.8% net income margin and has beaten earnings estimates for three consecutive quarters. Recent corporate actions include the completion of the Public Storage Canada acquisition and a $3.00 dividend declared for payment in October 2026. Analyst consensus is a Buy with a $328.33 price target, implying potential upside.
The outlook is mixed; strong fundamentals and analyst support suggest long-term value, but near-term technical weakness and fluctuating cash flows pose risks. Investors should weigh the high valuation multiples against the company's operational resilience and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
